GlassScriptPhysician profile
Christopher A Toupin
NPI 1467618249
$8,172.18
in general payments reported to CMS, 2019-2025
47 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $598 · 2021: $700 · 2022: $1,522 · 2023: $1,424 · 2024: $1,488 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,652.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,068.01 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $862.30 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $774.50 | 2019-2025 | |
| Abbvie INC. | $748.15 | 2020-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $572.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $522.73 | 2022-2025 | |
| Lilly USA, LLC | $380.49 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Sumitomo Pharma America, INC. | $326.82 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $322.84 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.65 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $257.02 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $184.79 | 2019-2023 | Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $163.79 | 2023-2025 | Rexulti, Nuedexta |
| Dexcom, INC. | $146.67 | 2024-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $144.43 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Toupin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.